BioSante Pharmaceuticals to Present at Needham Conference

BioSante Pharmaceuticals, Inc. (Amex:BPA) today
announced that Stephen M. Simes, the Company's president and chief
executive officer, will present a corporate and clinical overview of
the Company at the 5th Annual Needham & Company Biotechnology &
Medical Technology Conference, taking place at the New York Palace
Hotel, June 14-15, 2006.
   Mr. Simes' presentation is scheduled for today at 4:00 p.m. EDT. A
live audio webcast of BioSante's presentation may be accessed at
http://www.wsw.com/webcast/needham15/bpa/ and a replay will be
available at the same link for 90 days.

   About BioSante Pharmaceuticals, Inc.

   BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver bioidentical
estradiol and testosterone. BioSante's lead products include
Bio-E-Gel(R) (transdermal estradiol gel) for the treatment of women
with menopausal symptoms, and LibiGel(R) (transdermal testosterone
gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel
new drug application (NDA) was submitted to the FDA in the first
quarter 2006. The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion. The transdermal
gel formulations used in the women's gel products are licensed by
BioSante from Antares Pharma Inc. The company also is developing its
calcium phosphate nanotechnology (CaP) for novel vaccines, including
avian flu and biodefense vaccines for toxins such as anthrax and
ricin, and drug delivery systems. Additional information is available
online at: www.biosantepharma.com.